Jens-Peter Gregersen, DVM, PhD
Jens-Peter Gregersen studied veterinary medicine and holds a PhD in virology and a specialist degree in veterinary microbiology. Since 1980 he worked in academic and industrial R&D and in various positions. His occupations in industry at Behringwerke, Hoechst, Biotech Australia, Chiron Vaccines, Novartis, and GSK mainly focused on vaccine research and development and product care/improvement activities. This included work on viral vaccines, such as MMR, HAV, polio, rabies, AIDS , SARS and influenza vaccines but also antihormonal and antiparasitic vaccines.
His work contributed to the improvement of several human vaccine processes and to the successful development and licensing of several veterinary vaccines, the first recombinant antiparasite vaccine (TickgardR), and the first cell culture-derived influenza vaccine (OptafluR/FlucelvaxR and the pandemic influenza vaccine (CelturaR). In addition he established himself as an expert in viral safety of biomedicinal products.
In 2016 Dr. Gregersen founded his own consultancy business.